File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.5009/gnl18425
- Scopus: eid_2-s2.0-85071732605
- PMID: 30919601
- WOS: WOS:000496945500003
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: New Biomarkers of Chronic Hepatitis B
Title | New Biomarkers of Chronic Hepatitis B |
---|---|
Authors | |
Keywords | Hepatitis B core-related antigen Hepatitis B virus RNA Biomarkers |
Issue Date | 2019 |
Publisher | Gut and Liver, Editorial Office. The Journal's web site is located at http://www.gutnliver.org/ |
Citation | Gut and Liver, 2019, v. 13 n. 6, p. 589-595 How to Cite? |
Abstract | Chronic hepatitis B (CHB) infection leads to clinically heterogeneous disease outcomes. Different viral markers are utilized to monitor treatment effects and predict risk of complications in patients with CHB. Hepatitis B core-related antigen (HBcrAg) is a novel serum composite viral protein whose performance has been proven to be superior to that of existing viral markers. It showed good correlation with intrahepatic covalently closed-circular DNA. Its profile differs drastically in patients in different disease phases, and the level declines with antiviral therapies. HBcrAg may be helpful for predicting hepatocellular carcinoma development and hepatitis B virus (HBV) reactivation in immunosuppressed patients. Another emerging measurable serum marker, HBV RNA, exists in the form of pregenomic RNA-containing virions. Its profile differs between patients in different disease phases in a similar manner to that of HBcrAg. HBV RNA is present in serum at lower levels than HBV DNA in treatment-naïve patients by 1–2 logs. In contrast, its level is higher than HBV DNA in patients receiving nucleos(t)ide analogues (NAs). A significant decline in serum RNA was observed in patients receiving novel antiviral therapies, including core protein allosteric modulators and RIG-1/NOD2 agonists. Both HBcrAg and HBV RNA may be helpful for predicting off-therapy sustained virological control in patients who stop long-term NA treatment. |
Persistent Identifier | http://hdl.handle.net/10722/269440 |
ISSN | 2023 Impact Factor: 3.4 2023 SCImago Journal Rankings: 1.255 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mak, LY | - |
dc.contributor.author | Seto, WK | - |
dc.contributor.author | Fung, J | - |
dc.contributor.author | Yuen, MF | - |
dc.date.accessioned | 2019-04-24T08:07:46Z | - |
dc.date.available | 2019-04-24T08:07:46Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Gut and Liver, 2019, v. 13 n. 6, p. 589-595 | - |
dc.identifier.issn | 1976-2283 | - |
dc.identifier.uri | http://hdl.handle.net/10722/269440 | - |
dc.description.abstract | Chronic hepatitis B (CHB) infection leads to clinically heterogeneous disease outcomes. Different viral markers are utilized to monitor treatment effects and predict risk of complications in patients with CHB. Hepatitis B core-related antigen (HBcrAg) is a novel serum composite viral protein whose performance has been proven to be superior to that of existing viral markers. It showed good correlation with intrahepatic covalently closed-circular DNA. Its profile differs drastically in patients in different disease phases, and the level declines with antiviral therapies. HBcrAg may be helpful for predicting hepatocellular carcinoma development and hepatitis B virus (HBV) reactivation in immunosuppressed patients. Another emerging measurable serum marker, HBV RNA, exists in the form of pregenomic RNA-containing virions. Its profile differs between patients in different disease phases in a similar manner to that of HBcrAg. HBV RNA is present in serum at lower levels than HBV DNA in treatment-naïve patients by 1–2 logs. In contrast, its level is higher than HBV DNA in patients receiving nucleos(t)ide analogues (NAs). A significant decline in serum RNA was observed in patients receiving novel antiviral therapies, including core protein allosteric modulators and RIG-1/NOD2 agonists. Both HBcrAg and HBV RNA may be helpful for predicting off-therapy sustained virological control in patients who stop long-term NA treatment. | - |
dc.language | eng | - |
dc.publisher | Gut and Liver, Editorial Office. The Journal's web site is located at http://www.gutnliver.org/ | - |
dc.relation.ispartof | Gut and Liver | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Hepatitis B core-related antigen | - |
dc.subject | Hepatitis B virus RNA | - |
dc.subject | Biomarkers | - |
dc.title | New Biomarkers of Chronic Hepatitis B | - |
dc.type | Article | - |
dc.identifier.email | Mak, LY: lungyi@hku.hk | - |
dc.identifier.email | Seto, WK: wkseto@hku.hk | - |
dc.identifier.email | Fung, J: jfung@hkucc.hku.hk | - |
dc.identifier.email | Yuen, MF: mfyuen@hku.hk | - |
dc.identifier.authority | Mak, LY=rp02668 | - |
dc.identifier.authority | Seto, WK=rp01659 | - |
dc.identifier.authority | Fung, J=rp00518 | - |
dc.identifier.authority | Yuen, MF=rp00479 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.5009/gnl18425 | - |
dc.identifier.pmid | 30919601 | - |
dc.identifier.pmcid | PMC6860035 | - |
dc.identifier.scopus | eid_2-s2.0-85071732605 | - |
dc.identifier.hkuros | 297462 | - |
dc.identifier.volume | 13 | - |
dc.identifier.issue | 6 | - |
dc.identifier.spage | 589 | - |
dc.identifier.epage | 595 | - |
dc.identifier.isi | WOS:000496945500003 | - |
dc.publisher.place | Korea, Republic of | - |
dc.identifier.issnl | 1976-2283 | - |